All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-05-16T14:33:53.000Z

Health Canada grants clearance for phase III SIERRA trial of iomab-b in R/R AML

May 16, 2017
Share:

Bookmark this article

On 10th May 2017, Health Canada granted clearance for the initiation of the pivotal phase III SIERRA trial of iomab-b (a radio-immunoconjugate of I-131 and a murine monoclonal antibody that targets CD45 [an antigen widely expressed on leukemia cells]) in patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at Canadian based clinical trial sites.  

The pivotal randomized phase III SIERRA study (NCT02665065) aims to evaluate the efficacy of iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic Hematopoietic Cell Transplant (HCT) in 150 patients (55 years and above) with R/R AML. The primary and secondary endpoints of this study are durable complete remission at 6 months and overall survival at 1 year, respectively.

The clearance granted by Health Canada allows the SIERRA trial to open in approximately 15­–20 clinical trial sites in Canada.

  1. GlobeNewswire. Actinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B. 2017 May 10. https://globenewswire.com/news-release/2017/05/10/981716/0/en/Actinium-Pharmaceuticals-Receives-Clearance-from-Health-Canada-to-Initiate-Pivotal-Phase-3-SIERRA-Trial-of-Iomab-B.html [Accessed 2017 May 10].
More about...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox